Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST

Jorge F Maspero, John Mark FitzGerald, Ian D Pavord, Megan S Rice, Jaman Maroni, Paul J Rowe, Gianluca Pirozzi, Nikhil Amin, Marcella Ruddy, Neil M H Graham, Ariel Teper, Megan Hardin, Jorge F Maspero, John Mark FitzGerald, Ian D Pavord, Megan S Rice, Jaman Maroni, Paul J Rowe, Gianluca Pirozzi, Nikhil Amin, Marcella Ruddy, Neil M H Graham, Ariel Teper, Megan Hardin

No abstract available

Keywords: asthma; asthma treatment; biologics; biomarkers; interleukins.

Conflict of interest statement

Maspero JF: AstraZeneca, Sanofi—consultant; GlaxoSmithKline, Menarini, Novartis, Uriach—speaker fees; Novartis—research grants. FitzGerald JM: AstraZeneca, GlaxoSmithKline, Novartis, Teva—advisory board; AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi—research funding paid directly to UBC; GlaxoSmithKline—unrestricted grants; AstraZeneca, GlaxoSmithKline, Novartis—speaker honoraria; Vancouver Coastal Health—educational material. Pavord ID: Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva—speakers’ honoraria; AstraZeneca, Teva—organization of educational events; Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GlaxoSmithKline, Knopp Biosciences, Merck, Merck Sharp & Dohme, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc., RespiVert, Sanofi, Schering‐Plough, Teva—advisory boards; AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Napp Pharmaceuticals, Teva—traveling grants; Chiesi—clinical trial support. Rice MS, Rowe P, Hardin M: Sanofi—employees, may hold stock and/or stock options in the company. Maroni J, Amin N, Ruddy M: Regeneron Pharmaceuticals, Inc.—employees and shareholders. Pirozzi G, Teper A: Sanofi—former employees, may hold stock and/or stock options in the company. Graham NMH: Regeneron Pharmaceuticals, Inc.—former employee and shareholder.

Figures

FIGURE 1

LS mean change from baseline during the 52‐week treatment period in: pre‐bronchodilator FEV1 (L) in (A) the ITT QUEST adolescent population and (B) the subgroup of adolescents with baseline blood eosinophils ≥150 cells/µL or FeNO ≥20; (C) post‐bronchodilator FEV1 (L) in the ITT QUEST adolescent population; percent predicted pre‐bronchodilator FEV1 (L) in (D) the ITT QUEST adolescent population and (E) the subgroup with baseline blood eosinophils ≥150 cells/µL or FeNO ≥20. FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ITT, intention‐to‐treat; LS, least squares; ppb, parts per billion; q2w, every 2 weeks; SE, standard error. *p < .05, **p < .01, ***p < .001 vs matched (p values based on change from baseline vs placebo)

FIGURE 2

Annualized severe exacerbation rate (AER) during the 52‐week treatment period. Adjusted AER in (A) the ITT QUEST adolescent population and (B) the subgroup of adolescents with baseline blood eosinophils ≥150 cells/µl or FeNO ≥20; unadjusted AER in (C) adolescents and (D) the subgroup with baseline blood eosinophils ≥150 cells/µl or FeNO ≥20 ppb. CI, confidence interval; FeNO, fractional exhaled nitric oxide; ITT, intention‐to‐treat; q2w, every 2 weeks